• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a method for producing a crude extract enriched with pentacyclic triterpenes, including celastrol, from cells of a plant of the family Celastraceae; an enriched crude extract obtainable by such a method; therapeutic applications of such an extract; and pharmaceutical and dermocosmetic compositions containing such an extract.
    公开号:FR3051116A1
    申请号:FR1654240
    申请日:2016-05-12
    公开日:2017-11-17
    发明作者:Thien Nguyen；Adrien Cousy；Nicolas Steward
    申请人:Pierre Fabre Dermo Cosmetique SA；
    IPC主号:
    专利说明:

    The present invention relates to a process for producing a crude extract enriched with pentacyclic triterpenes, in particular Celastrol, from a plant cell culture (CCV) in suspension of a plant of the family Celastraceae.
    Tripterygium wilfordii is a medicinal plant belonging to the family Celastraceae, used for centuries in Southeast Asia (including China) to treat inflammatory disorders, autoimmune diseases, and more recently cancer. Terpenes are among the most active components of the plant and are located mainly in the roots of the plant. Among them, a norfriedelane pentacyclic triterpene, Celastrol, is evaluated for its effectiveness in the treatment of obesity, rheumatoid arthritis, Crohn's disease and prostate cancer. The supply needs of Célastrol are therefore constantly increasing.
    Inflammatory dermatosis, especially psoriasis or atopic dermatitis, has multifactorial origins or causes. The reasons for these so-called autoimmune diseases are not yet fully understood but would be linked to a deregulation of the immune system, particularly in terms of cellular responses. Cellular responses can be classified into 3 categories: Th1, Th2 and recently Th17. Although psoriasis and atopic dermatitis present differences in clinical signs, they would have similarities, particularly in the expression of IL17 and IL22 characteristic of the Th17 response (Miyagaki et al., 2015). IL17 and IL22 would therefore be attractive targets for treating these diseases. Thus monoclonal antibodies directed against IL17, IL17R, IL22, IL23, TNF alpha have been developed to block the Th17 pathway (Lowes et al., 2014). These molecules are effective for the treatment of psoriasis, but have many side effects and induce an exorbitant treatment cost.
    Moreover, it is also known that the Th17 pathway is highly activated in lesions of patients with acne (Kelhala et al., 2014).
    Celastrol is commonly obtained by plant extraction processes from plants of the Celastraceae family involving the use of solvents. These modes of biosynthesis involve cycles of eight to ten years for a young plant growth to reach the maturity necessary to be sacrificed. In addition, the use of phytosanitary products makes the process expensive: external contaminants (heavy metals) can accumulate and the crude extract generated contains multiple metabolites requiring several steps of purification of this plant extract to isolate the fraction. triterpene. Moreover, these processes have low yields of Celastrol.
    The total chemical synthesis of Celastrol is possible (Camelio et al., 2015) but requires about twenty steps, which considerably increases the final cost of obtaining the product.
    An alternative solution has been to obtain Celastrol from cell cultures in suspension of stem cells generated from the roots or leaves of the plant. Recently Coppede's team (Coppede et al., 2014) was able to obtain a higher Celastrol level from a culture of M. ilicifolia cells than that obtained by conventional extraction from the plant (0.304 mg Celastrol). per g of dry matter, maximum concentration obtained after 8 days of culture, ie 8.85 times better than by the conventional extraction method). The team of Liu et al. (Liu et al., 2016) has also shown that by adding MeJa (methyl jasmonate) (of the order of 50 μΜ) in a culture of T. wilfordii plant cells, the amount of Celastrol is increased by 4.82 times compared to that of a culture without MeJa: the concentration in mg of Celastrol per g of dry matter is 0.752 mg / g (culture with MeJa) versus 0.154 mg / g (culture without MeJa).
    These methods make it possible to obtain improved yields of Celastrol. However, there is still a real need for economically viable processes and to obtain quickly Celastrol in large quantities.
    The present invention provides a method of producing a crude extract enriched with Celastrol from plant cells of a plant of the family Celastraceae.
    Indeed, the inventors have developed a method for surprisingly increasing the yield of Celastrol in the culture of plant cells of a T. wilfordii line by using and comparing various combinations of elicitors. The inventors have indeed observed in particular that the cell division and the production of Celastrol are not concomitant. Surprisingly, they are even incompatible. To solve this problem, the inventors have developed a method comprising a cell proliferation step and an elicitation step with a cocktail of eliciting agents which stops the cell division. The inventors have furthermore demonstrated that the use of pairs of elicitors, in particular methyl jasmonate (MeJa) and chitin, makes it possible to obtain a concentration of 16.6 mg / g of Celastrol per dry weight at the end. of culture. The Celastrol yield of this crop is then 22 times higher than that obtained by Liu et al. (op cit). The yield by the process according to the invention is, moreover, 57 times higher than that obtained by Coppede et al. (op cit) without elicitation. The method according to the invention also makes it possible to enrich in derivatives of Celastrol, in particular of the pentacyclic tripterpene type, such as Tingenin A (also called Tingenone or Maytenin), Tingenine B (also called 22 beta-hydroxy-tingenone), the Pristimerin and Tripterygone.
    Furthermore, the inventors have surprisingly shown that a crude extract enriched with pentacyclic triterpenes obtained by this method inhibits with a dose effect Th17-specific interleukins induced in human TCD4 + cells.
    The present invention therefore relates to a method for producing a crude extract enriched with pentacyclic triterpenes comprising the following steps: (i) a cell proliferation phase of a plant of the family Celastraceae in a proliferation medium, (ii) an elicitation phase by adding an elicitation cocktail to the cell culture obtained in step (i), said elicitation cocktail comprising at least one elicitor of the monocarboxylic compound type and at least one biotic elicitor, and iii) preparing a crude extract enriched with pentacyclic tripterpenes from the cell culture obtained in step (ii).
    Furthermore, the present invention relates to an extract obtainable by the method according to the invention, as well as its uses.
    The term "pentacyclic triterpenes" according to the invention is understood to mean the pentacyclic triterpenes naturally produced by the cells of a plant of the family Celastraceae and in particular Celastrol (of formula I), Tingenin A (also called Tingenone or Maytenin) ( of formula II), Tingenine B (also called beta-hydroxy-tingenone) (of formula III), Pristimerine (of formula IV) and Tripterygone (of formula V), in particular Celastrol, Tingenin A and Tingenin B , notably Célastrol.
    (I) CELASTROL (II) TINGENINE A
    (III) TINGENIN B (IV) PRISTIMERIN
    (V) TRYPTERYGONE
    By "crude extract enriched with pentacyclic triterpenes" according to the invention is meant an enriched crude extract comprising an amount of pentacyclic triterpenes at least 2 times, in particular at least 5 times, in particular at least 10 times, in particular between 10 and 100 times higher. to that obtained by a method in the absence of an elicitation phase according to the invention.
    By "crude extract enriched with Celastrol" according to the invention is meant an enriched crude extract comprising a quantity of Celastrol at least 2 times, in particular at least 5 times, in particular at least 10 times, in particular between 10 and 60 times, especially between 10 and 20 times higher than that obtained by a method in the absence of an elicitation phase according to the invention.
    By "plant of the family of Celastraceae" according to the invention is meant all the plants belonging to this family, including plants of the genus Tripterygium, Bhesa, Kokkona, Catha, Euonymus, Orthosphenia, Dicarpellum, Celastrus, Maytenus, Peritassa and Rzedowskia, including Tripterygium and Celastrus. Among the genus Tripterygium, there may be mentioned the species Tripterygium wilfordii, Tripterygium regeli, Tripterygium hypoglaucum or Tripterygium articulata, including Tripterygium wilfordii.
    By "cells of a plant of the family of Celastraceae" according to the invention is meant the cells of any part of the plant: seeds, roots, aerial parts, including aerial parts.
    By "aerial parts" according to the invention is meant those parts of the plant located above the ground, for example, leaves, stems, petioles and / or inflorescences, especially leaves.
    According to the invention, the term "proliferation phase of cells of a plant of the family of Celastraceae" is intended to mean a phase in which the cells of a plant of the family Celastraceae are suspended in a proliferation medium and in conditions adapted to their proliferation. These cells may in particular be obtained from calli before they are suspended. If necessary, the cell suspensions can be regularly reseeded to keep them in proliferation conditions.
    By "cal" according to the invention is meant a cluster of dedifferentiated cells, also called stem cells or meristematic cells. Callus induction can be obtained by any method known to those skilled in the art. The calli according to the invention may in particular be obtained in the manner described below. Callus induction from an explant of plant part tissue, especially an aerial part, of the Celastraceae family, for example from Tripterygium wilfordii, is well known to those skilled in the art. The induction of calli may in particular be carried out by: obtaining an explant of plant tissue, for example a piece of leaf approximately 1 cm 2 in size, culturing the explant on a proliferation medium according to the invention; agaric invention (for example by adding 4 to 12 g / l of agar, for example about 8 g / l of agar, to the proliferation medium according to the invention), incubation, especially in the dark, at a temperature of about 25-30 ° C, for example at about 27 ° C to 28 ° C.
    Step (i): Proliferation Phase of Cells Those skilled in the art knowing the cell cultures of a plant of the family of the Celatraceae can easily determine the composition of the proliferation medium necessary for their proliferation. Preferably, this proliferation medium will allow proliferation of cells in dedifferentiated forms, that is to say in totipotent forms. The maintenance in dedifferentiated form may in particular be obtained by the use of particular cytokinin / auxin ratios in the proliferation medium.
    The "proliferation medium" according to the invention may especially comprise: at least one macroelement, in particular chosen from NH 4 NO 3, KNO 3, CaCl 2 .2H 2 O, MgSO 4 .7H 2 O, KH 2 PO 4 and a mixture thereof, for example at a concentration of macro-elements total between 1000 and 9000 mg / L, for example between 3000 and 8000 mg / L of proliferation medium: during the proliferation phase, the total macroelements concentration of the proliferation medium will be in particular between 3000 and 5500 mg / L of proliferation medium; at least one microelement, chosen in particular from Kl, H3BO3,
    MnSO4.4H2O, ZnSO4 .H2O, Na2MoO4.2H2O, CuSO4.5H2O, CoCl2.6H2O,
    FeSO4.7H2O, Na2EDTA.2H2O and a mixture thereof, for example at a total microelement concentration of between 10 and 200 mg / L, in particular between 50 and 150 mg / L of proliferation medium; at least one vitamin, chosen in particular from myo-inositol, nicotinic acid, pyridoxine-HCl, thiamine-HCl and a mixture thereof, for example at a total vitamin concentration which may range from 0.01 at 3 g / L, in particular from 0.05 to 1 g / L of proliferation medium; at least one amino acid, in particular glycine, for example at a total amino acid concentration which may range from 0.15 to 5 mg / l, in particular from 1 to 4 mg / l of proliferation medium: during the proliferation, the amino acid concentration of the proliferation medium will be in particular between 1 and 2.5 mg / L of proliferation medium; at least one carbon source, especially sucrose, for example at a total carbon source concentration of 10 to 70 g / l of proliferation medium, for example at approximately 30 g / l; at least one plant hormone (also called plant growth hormone or plant growth factor or plant growth regulator) especially chosen from one or more cytokinins, in particular kinetin and / or 6-furfurylaminopurine, one or more auxins, especially 2,4-dichlorophenoxyacetic acid (2,4D) and / or naphthalene acetic acid (NAA), and a mixture thereof. During the prolferation phase, the proliferation medium will comprise in particular at least one cytokinin and at least one auxin.
    In particular, the plant growth hormones will be added to the proliferation medium at a concentration and a ratio allowing proliferation of the cells in dedifferentiated forms. They will be chosen in particular from kinetin, 6-furfurylaminopurine, 2,4-dichlorophenoxyacetic acid (2,4D), naphthalene acetic acid (NAA) and a mixture thereof; especially chosen from kinetin, 2,4-dichlorophenoxyacetic acid (2,4 D), naphthalene acetic acid (NAA) and a mixture thereof. It may be in particular a mixture of kinetin, 2,4-dichlorophenoxyacetic acid (2,4D) and naphthalene acetic acid.
    The concentration of auxins according to the invention will in particular be between 0.001 and 10 mg / L of proliferation medium, for example between 0.1 and 3 mg / L of proliferation medium.
    The concentration of cytokinins according to the invention will in particular be between 0.01 and 0.5 mg / L of proliferation medium, in particular between 0.05 and 0.15 mg / L.
    In one embodiment, the auxin / cytokinin hormone ratio will be between 0.2 to 2.5 / 0.01 to 0.5, in particular between 1 to 0.05 to 0.2 in particular will be approximately 1, 5 / 0.1.
    In particular, the proliferation medium according to the invention may comprise 1.5 mg / L of auxin, in particular 2,4-dichlorophenoxyacetic acid (2,4 D) and naphthalene acetic acid (NAA), and 0.1 mg / L of cytokinin, including kinetin.
    The proliferation medium will be sterile and preferably at a pH close to neutrality.
    An example of a proliferation medium adapted to the proliferation of cells of a plant of the family Celastraceae according to the invention is described in particular by Murashige & Skoog (1962) or in the examples of this application.
    This proliferation medium may for example have the following composition (concentrations are expressed relative to the volume of cell-free proliferation medium): Macroelements: NH4NO3 at 1650 mg / L, KNO3 at 1900 mg / L, CaCl2.2H2O at 440 mg / L, MgSO 4 .7H 2 O at 370 mg / L, KH 2 PO 4 at 170 mg / L; Microelements: KI at 0.83 mg / L, H3BO3 at 6.2 mg / L, MnSO4.4H2O at 22.3 mg / L, ZnSO4 .H2O at 6.6 mg / L, Na2MoO4.2H2O at 0.25 mg / L, 0.025 mg / L CuS04.5H2O, 0.025 mg / L CoCl2.6H2O, 27.8 mg / L FeS04.7H2O, 37.3 mg / L Na2EDTA.2H2O; Vitamins: myo-inositol 100 mg / L, nicotinic acid 0.5 mg / L, pyridoxine-HCI 0.5 mg / L, thiamine-HCI 0.5 mg / L; Amino acids: glycine at 2 mg / L; Carbon source: sucrose at 30g / L; and vegetable hormones: naphthalene acetic acid 1 mg / L, 2,4-dichlorophenoxyacetic acid 0.5 mg / L, kinetin 0.1 mg / L, all adjusted to pH 6 before sterilization (for example by autoclaving 20 min at 121 ° C or by filtration on a 0.2 μm filter).
    Alternatively, the proliferation medium may have the following composition: (concentrations are expressed relative to the volume of proliferation medium without cell): Macroelements: NH4NO3 at 1650 mg / L, KNO3 at 2500 mg / L, CaCl2.2H2O at 440 mg / L, MgSO 4 .7H 2 O at 370 mg / L, KH 2 PO 4 at 130 mg / L; Microelements: KI at 0.41 mg / L, H3BO3 at 6.2 mg / L, MnSO4.4H2O at 22.3 mg / L, ZnSO4 .H2O at 7.5 mg / L, Na2MoO4.2H2O at 0.25 mg / L, 0.025 mg / L CuS04.5H2O, 0.025 mg / L CoCl2.6H2O, 19.85 mg / L FeS04.7H2O, 26.64 mg / L Na2EDTA.2H2O; Vitamins: myo-inositol 50 mg / L, nicotinic acid 0.25 mg / L, pyridoxine-HCI 0.25 mg / L, Thiamine-HCI 0.25 mg / L; Carbon source: sucrose at 30 g / L; and Plant hormones: 0.083 mg / L kinetin, 2,4-dichlorophenoxyacetic acid (2,4 D) at 0.575 mg / L, naphthalene acetic acid (NAA) at 0.350 mg / L.
    Alternatively, the proliferation medium according to the invention may have the following composition (the concentrations are expressed relative to the volume of cell-free proliferation medium): NH 4 NO 3 at 20 mM, KNO 3 at 19 mM, CaCl 2 .2H 2 O at 3 mM, MgSO 4. 1.50 mM, 1.2 mM KH 2 PO 4, KCl to 0.005 mM, 0.1 mM H 3 BO 3, 0.1 mM MnSO 4 .4H 2 O, 0.04 mM ZnSO 4 .H 2 O, 0.001 mM Na 2 MoO 4 .2H 2 O , 0001 mM, 0.0001 mM CoCl2.6H2O, 0.1 mM FeSO4.7H2O, 0.1 mM Na2EDTA.2H2O, 0.5mM myo-inositol, 0.004mM nicotinic acid, 0.002mM pyridoxine-HCl 0.0015mM thiamine-HCl, 0.03mM glycine, 87.6mM sucrose, 0.005mM naphthalene acetic acid, 0.002mM 2,4-dichlorophenoxyacetic acid, and 0.0005mM kinetin. Seeding of the proliferation medium may be carried out starting from suspension of callus cells at a concentration of between 20 and 300 g in 1 L of proliferation medium and preferably between 100 and 200 g in 1 L of proliferation medium. for example, about 150 g in 1 L of proliferation medium.
    The proliferation phase will take place under conditions of biomass multiplication. By "biomass multiplication conditions" according to the invention is meant in particular the conditions of temperature, duration, agitation, and brightness necessary for the proliferation of cells in suspension. Those skilled in the art knowing the cultures of cells of a plant of the family of Celatraceae can easily determine the conditions of multiplication of the biomass. In one embodiment of the invention, the biomass proliferation step will be carried out in the dark, at a temperature of between 20 and 35 ° C., in particular between 27 and 28 ° C., in particular at about 27 or 28 ° C. ° C, in particular with stirring of between 100 and 200 rpm, in particular at about 125 rpm (orbital of 22.5 mm) and for a period of between 10 and 30 days, in particular 15 days of culture.
    During this step, the cells can be "transplanted" or propagated, for example every 7 to 15 days. Transplanting cells is well known to those skilled in the art, it may include diluting a portion of the cell culture in concentrated new medium. For example, 1 / 5th of the culture is resuspended in a volume of new medium corresponding to the volume of the initial culture. It allows the maintenance of the cell line in a liquid medium in a state of proliferation.
    Step (ii) - elicitation phase
    After the proliferation phase, the cells obtained in phase (i) are elicited by adding an elicitation cocktail. The proliferation medium to which the elicitation cocktail has been added will be named "elicitation medium" according to the present invention.
    The elicitation phase is the phase in which the cells are maintained in a physiological state promoting the biosynthesis of secondary metabolites such as pentacyclic triterpenes.
    The production of pentacyclic triterpenes, in particular Celastrol, takes place, during the elicitation phase, in the cytosol of the cell and can partly diffuse into the elicitation medium. The elicitation phase within the meaning of the present invention therefore corresponds to the production phase (biosynthesis) of Celastrol and its derivatives (pentacyclic triterpenes). The elicitation will be preferably after a proliferation phase of 7 to 21 days, including 12 to 20 days, including 15, 16 or 17 days (including without transplanting). Alternatively, the addition of the elicitation cocktail may be done when the cell concentration obtained during the proliferation phase is double, especially greater than twice, relative to the initial concentration of cells in the proliferation medium. The addition of the elicitation cocktail may especially be done when the cell concentration is greater than 200 g / l, for example between 200 and 400 g / l, in particular about 300 g / l (in the amount of cells per liter of medium proliferation). In one embodiment, the addition of the elicitation cocktail will be in a culture whose cell concentration has increased from 150 to 200 g / L at the beginning of the proliferation phase at a concentration of between 300 and 400 g. / L at the end of the proliferation phase. As a result of the proliferation phase, the plant cells have consumed most or all of the elements contained in the proliferation medium, and in particular carbon sources such as sucrose. It may therefore be necessary to restore the composition of the medium before or at the same time as adding the elicitation cocktail.
    In order to restore the composition of the medium, it is possible in particular to concentrate the cell culture obtained after the proliferation step, for example by decantation or filtration, and then add new proliferation medium to the cells thus obtained. In this case, the cells will be resuspended in the new proliferation medium so as to obtain a concentration of between 200 g / l and 400 g / l, for example between 250 and 350 g / l, in particular about 300 g / L (in amount of cells per liter of proliferation medium).
    Alternatively, a concentrated mixture can be added to the cell culture to restore the concentrations of the elements of the proliferation medium. The concentrated mixture will be added just before, just after or at the same time as the elicitation cocktail. For example, one-fifth of the cell culture can be replaced by an equivalent volume of the proliferation medium concentrated five times.
    It is considered that the concentration of elements of the proliferation medium is close to or equivalent to zero after 14, 15 or 16 days of proliferation phase. In particular it is considered that the concentration of mineral elements (more particularly macroelements and microelements) and carbon (especially carbon sources) is close to or equivalent to zero after 14, 15 or 16 days of proliferation phase.
    In one embodiment, the proliferation medium according to the invention at the beginning of the elicitation phase will comprise among others: at least one macroelement, in particular chosen from NH 4 NO 3, KNO 3, CaCl 2 .2H 2 O, MgSO 4 .7H 2 O, KH 2 PO 4 and a mixing them, for example at a total macroelement concentration of between 5000 and 8000 mg / L, preferably greater than 6000 mg / L of proliferation medium, advantageously between 6000 and 8000 mg / L; at least one microelement, chosen in particular from Kl, H3BO3,
    MnSO4.4H2O, ZnSO4 .H2O, Na2MoO4.2H2O, CuSO4.5H2O, CoCl2.6H2O,
    FeSO4.7H2O, Na2EDTA.2H2O and a mixture thereof, for example at a total microelement concentration of between 10 and 200 mg / L, in particular between 50 and 150 mg / L of proliferation medium; at least one vitamin, chosen in particular from myo-inositol, nicotinic acid, pyridoxine-HCl, thiamine-HCl and a mixture thereof, for example at a total vitamin concentration which may range from 0.01 at 3 g / L, in particular from 0.05 to 1 g / L of proliferation medium; at least one amino acid, in particular glycine, for example at a concentration in the proliferation medium of between 3 and 4 mg / l of proliferation medium; at least one carbon source, especially sucrose, for example at a total carbon source concentration of 10 to 70 g / l of proliferation medium, for example at approximately 30 g / l;
    In one embodiment the proliferation medium at the beginning of the elicitation phase will not include, where will comprise a negligible amount, especially less than 0.001 g / ml, of cytokinin and auxin.
    The proliferation medium during the elicitation phase will be advantageously sterile and preferably at a pH close to neutrality.
    The proliferation medium during the elicitation phase may notably have the following composition: Macroelements: NH4NO3 at 2.8 g / L, KNO3 at 3 g / L, CaCl2.2H2O at 0.45 g / L, MgSO4 .7H2O at 74 mg / L, KH2PO4 at 34 mg / L; Microelements: KI at 0.16 mg / L, H3BO3 at 6.2 mg / L, MnSO4.4H20 at 18.5 mg / L, ZnSO4 .H2O at 6.6 mg / L, Na2MoO4.2H2O at 0.25 mg / L , 0.025 mg / L CuS04.5H2O, 0.025 mg / L CoCl2.6H2O, 28 mg / L FeS04.7H2O, 37 mg / L Na2EDTA.2H2O; Vitamins: myo-inositol 250 mg / L, nicotinic acid 1.7 mg / L, pyridoxine-HCl 1 mg / L, thiamine-HCl 1 mg / L; Amino acid: glycine at 4 mg / L; Carbon source: sucrose at 30 g / L.
    By "elicitation cocktail" according to the invention is meant a cocktail for stopping cell division. This elicitation cocktail comprises at least one monocarboxylic compound elicitor and at least one biotic elicitor. The elicitation cocktail is introduced, for example, using concentrated stock solutions in the culture medium.
    By "monocarboxylic compound elicitor" according to the invention is more particularly meant an elicitor selected from the group consisting of, preferably consisting of 5-chloro-salicylic acid (5-Chloro SA), salicylic acid (SA ), acetyl salicylic acid (ASA), a methyl ester, especially methyl jasmonate (MeJa), and a mixture thereof. In one embodiment of the invention, the monocarboxylic compound elicitor is methyl jasmonate, salicylic acid and / or 5-chloro-salicylic acid, especially methyl jasmonate. The elicitor of the monocarboxylic compound type will in particular be added so as to obtain a final concentration of between 0.005 and 0.1 g / l, especially 0.01 and 0.05 g / l of elicitation medium, in particular of 0.002 and 0.004. g / L of elicitation medium.
    By "biotic elicitor" according to the invention is more particularly meant a biotic elicitor selected from the group consisting of, preferably consisting of N-acetylaminoglucosamine, including chitin, chitosan, extracts of microorganisms or fungi, oligosaccharides (polysaccharides, pectins, cellulose). In one embodiment, the biotic elicitor is chitin. Chitin is a linear polymer of repeating unit: beta-1,4 N-acetyl D-glucosamine. The biotic elicitor will in particular be added so as to obtain a final concentration of between 0.05 and 50 g / l of elicitation medium, for example from 0.1 to 10 g / l, for example from 0.5 to 7 g / l. g / L, in particular from 1 to 5 g / L of elicitation medium.
    In one embodiment, the elicitation cocktail comprises methyl jasmonate, in particular at a final concentration in the elicitation medium of between 0.002 and 0.005 g / L, and chitin, in particular at a final concentration of between 1 and 4. g / L of elicitation medium.
    In one embodiment, the elicitation cocktail according to the invention will also comprise at least one cell-cell differentiation factor of the plant cells and / or at least one precursor of the terpenes synthesis pathway.
    The "cell cell differentiation factor of the plant cells" according to the invention may especially be chosen from the group comprising, preferably consisting of a cytokinin, in particular benzylaminopurine (BAP), abscisic acid, kinetin, thidiazuron , 6-γ, γ-dimethylallylaminopurine (2iP or isopentenyladenine) or zeatin, a gibberellin and a mixture thereof, especially BAP and / or 2iP, in particular 2iP.
    The "terpene synthesis precursor" according to the invention may in particular be selected from the group comprising, preferably consisting of, sodium pyruvate; potassium pyrophosphate; mevalonic acid; geraniol; farnesol; isopentenyl, dimethylallyl, including their pyrophosphate forms; sodium acetate; pyruvic acid and mixtures thereof, especially geraniol, farnesol, sodium pyruvate, potassium pyrophosphate and mixtures thereof, such as sodium pyruvate and / or potassium pyrophosphate.
    The BAP may in particular be used at a final concentration in the elicitation medium of between 0.01 and 5 mg / L, for example between 0.5 and 5 mg / L of elicitation medium. The 5-chloro-salicylic acid (5-Chloro SA) may in particular be used at a final concentration in the elicitation medium of between 0.1 and 15 mg / l. Salicylic acid may in particular be used at a final concentration in the elicitation medium of between 0.1 and 100 mg / l, for example between 20 and 60 mg / l, for example approximately 45 mg / l.
    Farnesol may especially be used at a final concentration in the elicitation medium of 1 to 100 mg / l, for example 15 to 30 mg / l, for example at about 30 mg / l.
    Geraniol may especially be used at a final concentration in the elicitation medium of 1 to 100 mg / l, for example 20 to 30 mg / l.
    In particular, sodium pyruvate may be used at a final concentration in the elicitation medium of 100 to 5000 mg / l, for example 500 to 2000 mg / l.
    Potassium pyrophosphate may in particular be used at a final concentration in the elicitation medium of 1 to 2000 mg / l, for example 100 to 1000 mg / l of elicitation medium.
    The 2iP may especially be used at a final concentration in the elicitation medium of 0.005 to 10 mg / l, for example from 0.01 mg / l to 3 mg / l, for example from 0.1 to 2 mg / l.
    In one embodiment of the invention, the elicitation cocktail comprises methyl jasmonate, chitin, sodium pyruvate, potassium pyrophosphate or a mixture thereof.
    In one embodiment of the invention, the elicitation cocktail comprises methyl jasmonate, chitin, sodium pyruvate, potassium pyrophosphate, and optionally BAP and / or 2iP.
    In one embodiment of the invention, the elicitation cocktail comprises or consists of (the concentrations given in parentheses correspond to the concentration in the elicitation medium, the initial cocktail may be more or less concentrated depending on the dilution sodium pyruvate (from 500 to 2000 mg / L), potassium pyrophosphate (from 100 to 1000 mg / L), 2iP (from 0.1 to 2 mg / L), methyl jasmonate ( 0.002 to 0.005 g / L) and chitin (1 to 4 g / L).
    In another embodiment, the elicitation cocktail comprises or consists of (the concentrations given in parentheses correspond to the concentration in the elicitation medium, the initial cocktail may be more or less concentrated depending on the dilution envisaged) of benzylaminopurine (BAP) (0.5 to 5 mg / L, especially 0.5 to 3 mg / L); 5-chloro-salicylic acid (5-Chloro SA) (from 2 to 6 mg / L, especially from 3 to 5 mg / L, for example to about 3 or about 5 mg / L), acid acetylsalicylic acid (ASA) and / or salicylic acid (SA) (from 20 to 60 mg / L, in particular from 30 to 50 mg / L, in particular from 33 to 45 mg / L); methyl jasmonate (MeJA) (from 0.002 to 0.005 g / L, especially from 10 to 40 mg / L); chitin (1 to 4 g / L); and farnesol (F-OH) (19 to 40 mg / L) and / or geraniol (20 to 30 mg / L).
    In another embodiment, the elicitation cocktail comprises or consists of (the concentrations given in parentheses correspond to the concentration in the elicitation medium, the initial cocktail may be more or less concentrated depending on the dilution envisaged) of the pyruvate (from 500 to 2000 mg / L), potassium pyrophosphate (from 100 to 1000 mg / L), 2iP (from 0.1 to 1 mg / L), methyl jasmonate (MeJA) (from 0.002 to 0.005 g / L, especially 10 to 40 mg / L) and chitin (1 to 4 g / L).
    In another embodiment, the elicitation cocktail comprises or consists of (the concentrations given in parentheses correspond to the concentration in the elicitation medium, the cocktail being more or less concentrated depending on the dilution envisaged) of the pyruvate of sodium (about 1.5 g / L), potassium pyrophosphate (about 0.4 g / L), 2iP (about 0.4 mg / L), methyl jasmonate (MeJA) (about 0.03 mg / L), chitin (about 2 g / L).
    During the elicitation phase, after addition of the elicitation cocktail, the culture is kept under agitation, in particular between 50 and 200 rpm, especially at about 125 rpm, for a period of between 3 and 30 days, in particular between 10 and 25 hours. days, especially 12 to 15 days, in particular at a temperature between 20 and 35 ° C, especially at about 27 ° C and preferably with a dissolved oxygen level in the culture medium of 2 to 40%, preferably at about 16%. An injection of sterile air sufficiently enriched with oxygen may be provided if necessary, especially in the dead volume of the bioreactor or by diffusion in the medium. Preferably, the elicitation phase (iii) is conducted in the dark. During the elicitation phase, the cell culture is preferentially not transplanted.
    Step (iii) - phase of preparation of the crude extract enriched with pentacyclic triotenenes
    After the elicitation phase, the process according to the invention comprises a step of preparation of a crude extract enriched with pentacyclic tripterpenes, in particular Celastrol. The enriched crude extract may in particular be obtained by separation of the biomass and the culture supernatant. The separation may especially be carried out by direct filtration (0-50 pm), by centrifugation or by decantation of the cells.
    In one embodiment, the crude enriched extract according to the invention may consist of the culture supernatant thus recovered. The enriched crude extract according to the invention may also be obtained after the lysis of the biomass. For example, the cells contained in the biomass recovered can be lysed by a physical method (sonication or grinding) or chemical (acid lysis) and then this lysate will be subjected to solvent extraction. The organic phase, including in particular the triterpenes from the cytosol, is then recovered, in particular by decantation or centrifugation.
    The solvent will in particular be an ester solvent, and more particularly an alkyl acetate, the alkyl being more particularly linear or branched to 1 to 6 carbon atoms, in particular ethyl acetate or isopropyl acetate. . The volume of solvent used will be in particular 2 volumes by weight of biomass.
    Preferably, the enriched crude extract according to the invention will correspond to the organic phase thus recovered.
    Alternatively, the enriched crude extract according to the invention may be obtained after evaporation of the solvent and its substitution in particular by a support adapted to the field of use of the extract (cosmetic, pharmaceutical) and in particular vegetable oils. The enriched crude extract according to the invention is not purified. The crude enriched extract may optionally be purified at a later stage.
    When the enriched crude extract is purified to give a purified extract, the process according to the invention further comprises a step (iv) of obtaining a purified extract of one or more pentacyclic triterpenes from the extract enriched crude obtained in step (iii). The purified extract according to the invention will then comprise more than 90%, especially more than 95%, especially more than 98% of one or more pentacyclic triterpenes according to the invention. In one embodiment, the purified extract according to the invention comprises more than 90%, in particular more than 95%, in particular more than 98% of Celastrol, in particular 100% of Celastrol.
    The purification of the enriched extract according to the invention may in particular be carried out by a separation phase of the pentacyclic triterpene (s), in particular Celastrol, Tingenin A and Tingenin B, in particular by HPLC (high performance liquid chromatography) fractionation, in particular, the peaks at 426 nm comprising Célastrol, Tingenin A and Tingénine B leave respectively at 10.5 min, 8.2 min and 6.5 min. The purification of Celastrol may in particular be carried out as described in the examples of the present application.
    The present invention further relates to a crude enriched extract obtainable by the process according to the invention.
    Another subject of the invention relates to a pharmaceutical composition, such as dermatological, or dermocosmetic, comprising a crude enriched extract obtainable by the method according to the invention and one or more pharmaceutically or dermocosmetically acceptable excipients.
    The pharmaceutically or dermocosmetically excipients can be any excipient among those known to those skilled in the art. The composition according to the invention will in particular be a topical composition, especially in the form of a cream, a lotion, a gel, an ointment, an emulsion, a microemulsion, a spray, etc.
    The pharmaceutical composition, such as dermatological or dermocosmetic according to the invention may in particular contain additives and formulation aids, such as emulsifiers, thickeners, gelling agents, water binders, spreading agents, stabilizers, dyes, fragrances and preservatives.
    Another object according to the invention is a crude enriched extract obtained by the process according to the invention for its use as a medicament, in particular in the treatment or prevention of an inflammatory dermatosis inducing a TH17 mediated cellular response. Those skilled in the art can easily determine inflammatory dermatoses inducing a TH17-mediated cellular response. Those skilled in the art may in particular measure the level of expression of IL-22, IL-17 and / or TNF-α of an injured area relative to a control sample.
    The inflammatory dermatosis according to the invention may in particular be selected from the group comprising, preferably consisting of, psoriasis, atopic dermatitis and acne.
    The present invention is illustrated by the figures and non-limiting examples detailed below. FIGURES: FIGURE 1: Growth curve (solid line) of a cell culture of Trypterigium wilfordii in g / L of wet biomass (FW) versus time in days and concentration of Celastrol (dashed line) in mg of Celastrol per L of cell suspension as a function of time in days. FIG. 2: HPLC chromatogram (λ = 426 nm) of the enriched crude extract of Tripterygium wilfordii obtained at J33. FIGURE 3: Percentage of induction of IL-17A synthesis by CD4 + T lymphocytes after incubation with samples 2, 3, 4 and 5 compared to the negative control incubated with sample 1 followed by stimulation with anti-CD3 and anti-CD28 antibodies (*** p value <0.001). FIGURE 4: Percentage of induction of INF-γ synthesis by CD4 + T lymphocytes after incubation with samples 2, 3, 4 and 5 compared to the negative control incubated with sample 1 followed by stimulation with anti-CD3 and anti-CD28 antibodies (*** p value <0.001). FIGURE 5: Percentage of induction of IL-22 synthesis by CD4 + T lymphocytes after incubation with samples 2, 3, 4 and 5 compared to the negative control incubated with sample 1 followed by stimulation with anti-CD3 and anti-CD28 antibodies (*** p value <0.001). FIGURE 6: Percentage of induction of TNF-α synthesis by CD4 + T lymphocytes after incubation with samples 2, 3, 4 and 5 compared to the negative control incubated with sample 1 followed by stimulation with antibodies anti-CD3 and anti-CD28 (*** p value <0.001). FIGURE 7: Percentage of Induction of IL-6 Synthesis by CD4 + T-cells after Incubation with Specimens 2, 3, 4 and 5 vs. Negative Control Incubated with Sample 1 followed by Stimulation with anti-CD3 and anti-CD28 antibodies (*** p value <0.001). EXAMPLES
    Example 1: Cell Dedifferentiation Protocol
    Calli are obtained from leaf explants of Tripterygium wilfordii.
    The explants are sterilized with 70% ethanol and then with sodium hypochlorite containing 2.5% of active chlorine, then rinsed with sterile demineralized water. Optionally, a wash with 7% hydrogen peroxide before rinsing with sterile demineralized water is possible.
    The leaves are cut into pieces, for example in squares of about 8-10 mm side. The leaf explants are deposited on an agaric medium of proliferation.
    The composition of the proliferation medium is as follows:
    Macroelements: NH4NO3 at 1650 mg / L, KNO3 at 1900 mg / L, CaCl2.2H2O at 440 mg / L, MgSO4.7H2O at 370 mg / L, KH2PO4 at 170 mg / L,
    Microelements: KI at 0.83 mg / L, H3BO3 at 6.2 mg / L, MnSO4.4H2O at 22.3 mg / L, ZnSO4 .H2O at 6.61 mg / L, Na2MoO4.2H2O at 0.25 mg / L, CuS04.5H20 at 0.025 mg / L, C0Cl2.6H2O at 0.025 mg / L, FeSC> 4.7H20 at 27.8 mg / L, Na2EDTA.2H20 at 37.3 mg / L,
    Vitamins: myo-inositol 100 mg / L, nicotinic acid 0.5 mg / L, pyridoxine-HCl 0.5 mg / L, thiamine-HCl 0.5 mg / L,
    Amino acid: glycine at 2 g / L,
    Carbon source: sucrose at 30 g / L,
    Plant hormones: 0.1 mg / L kinetin, 2,4-dichlorophenoxyacetic acid (2,4 D) at 0.5 mg / L, naphthalene acetic acid (NAA) at 1 mg / L.
    The growth medium is gelled by addition of agar at 8-12 g / L, its pH is adjusted to pH 6 ± 0.5 (with KOH, 1M) before autoclaving for 20 min at 121 ° C. The petri dishes containing the explants are incubated in the dark at 27-28 ° C.
    The transplanting of the calluses is carried out every month on the same agar medium. For this, the calluses obtained are detached from the leaf explant and deposited on new agar plates of proliferation medium.
    EXAMPLE 2 Formulation of Culture and Propagation Media (Proliferation Phase)
    After a few months of transplanting, friable calli are obtained and are transferred to liquid proliferation medium.
    The proliferation medium has, for example, the composition indicated below:
    Macroelements: NH4NO3 at 1650 mg / L, KNO3 at 2500 mg / L, CaCl2.2H2O at 440 mg / L, MgSO4.7H2O at 370 mg / L, KH2PO4 at 130 mg / L,
    Microelements: KI at 0.41 mg / L, H3BO3 at 6.2 mg / L, MnSO4.4H2O at 22.3 mg / L, ZnSO4 .H2O at 7.5 mg / L, Na2MoO4.2H2O at 0.25 mg / L, 0.025 mg / L CuS04.5H2O, 0.025 mg / L CoCl2.6H2O, 19.85 mg / L FeS04.7H2O, 26.64 mg / L Na2EDTA.2H2O,
    Vitamins: myo-inositol at 50 mg / L, nicotinic acid at 0.25 mg / L, pyridoxine-HCl at 0.25 mg / L, thiamine-HCl at 0.25 mg / L,
    Carbon sources: sucrose at 30 g / L,
    Plant hormones: kinetin 0.083 mg / L, 2,4-dichlorophenoxyacetic acid (2,4 D) at 0,575 mg / L, naphthalene acetic acid (NAA) at 0,350 mg / L.
    The pH of the medium is adjusted to pH 6 ± 0.5 (by addition of KOH, 1M) before an appropriate sterilization treatment, for example autoclave at 121 ° C. for a minimum of 20 minutes or by sterilizing filtration on 0.2 pm.
    The cell suspension is carried out by depositing about 40 g of friable calli in a 200 ml Erlenmeyer flask containing the propagation medium, incubation for one week on a stirring table at 100 RPM (rotation per minute) in the dark at 27-28 ° C. The cell supernatant is collected by pipette leaving residual callus clusters. The cell suspension obtained is cultured for 15 days and then propagated by dilution to 1 / 5th in new medium every 15 days.
    The filling rate of the Erlenmeyer flasks is 40% (80 ml) and the rate of inoculation by cell suspension transfer is 20-25% of the volume, ie approximately 160 g / l of fresh biomass. The culture is thus conducted for 15 days in the dark at 27-28 ° C with orbital shaking of 110-120 RPM. At this stage, the biomass is present at a concentration of 300 g / l of fresh biomass per liter of suspension.
    Example 3 Production of Triterpenes in Erlenmeyer (phase of elicitation and preparation of the enriched crude extract).
    Elicitation phase:
    After 15 days of culture, 1 / 5th of the cell culture is removed from the Erlenmeyer flask and 20 ml of a concentrated proliferation medium is added to the Erlenmeyer flask. The composition of the concentrated medium is as follows: Macroelements: NH4NO3 at 13.9 g / L, KNO3 at 15.2 g / L, CaCl2.2H2O at 2.2 g / L, MgSO4.7H2O at 370 mg / L, KH2PO4 at 170 mg / L; Microelements: KI at 0.83 mg / L, H3BO3 at 31.2 mg / L, MnSO4.4H2O at 91.5 mg / L, ZnSO4 .H2O at 33.05 mg / L, Na2MoO4.2H2O at 1.25 mg / L, CuS04.5H2O at 0.125 mg / L, CoCl2.6H2O at 0.125 mg / L, FeS04.7H2O at 139 mg / L, Na2EDTA.2H2O at 186.5 mg / L; Vitamins: myo-inositol at 1250 mg / L, nicotinic acid at 8.5 mg / L, pyridoxine-HCl at 5 mg / L, thiamine-HCl at 5 mg / L; Amino acid: glycine at 20 mg / L; Carbon source: sucrose at 150 g / L (solubilized in deionized water).
    The elicitation cocktail is then added to the Erlenmeyer flask in the medium of proliferation using stock solutions made in dimethylsulfoxide. The composition of the elicitor cocktail makes it possible to obtain the following concentrations in the elicitation medium (+ cells): sodium pyruvate 1.5 g / l, potassium pyrophosphate 0.440 g / l, 2 i P 0.0004 g / l, methyl jasmonate 0.036 g / L and chitin 2 g / L.
    The production of Celastrol and its derivatives is conducted for 12 days in the dark at 27-28 ° C with orbital shaking of 120 rpm. Harvesting biomass for extraction: When the crop is stopped, the medium is filtered to recover all of the biomass that contains the majority of Celastrol.
    After separation of the biomass by filtration 0-50 pm, 2 volumes of ester solvent and more particularly alkyl acetate, especially ethyl acetate (still isopropyl acetate), are mixed with 1 weight of biomass. This mixture is subjected to extraction by sonication to lyse the cells and make available the elements of the cytosol. The organic phase comprising the triterpene fraction is recovered after centrifugation of the mixture.
    The concentration of Celastrol in the organic phase is measured. The concentration of Celastrol per liter of suspension is estimated at 553 mg, which corresponds to a weight of 0.0166 g of Celastrol per gram dry weight of cells.
    EXAMPLE 4 Production of Triterpenes (Celastrol and Derivatives) in Single-Use WAVE-Type Bioreactors The example illustrated is described for WAVE-type reactors, for example, of the Sartorius brand, for volumes of 5 L or 10 L or 2 X 5 L, but the method can be adapted and applied to higher volumes and materials from other manufacturers.
    The previously described binary system for traditional glass or industrial laboratory bioreactors made of stainless steel is applied in the same way with the 2 WAVE bags.
    Proliferation:
    The Wave A (5 L) bioreactor, placed on its support, is filled with the proliferation medium by sterilizing filtration in line and inflated by air.
    A preculture of Trypterygium wilforddi is carried out for 15 days in Erlenmeyer flask as described in Example 2. The proliferation medium of the bioreactor is then inoculated with this preculture at a concentration of 160 g / l (pocket A).
    The bioreactor is incubated under the following conditions: - tilt angle: 5-8 °; - switching frequency: 16-30 RPM; aeration rate: 0.1-0.5 L / min of air enriched with 50% pure oxygen; temperature: 27 ° C .; - duration: 17 days.
    During this proliferation phase cell growth is measured every day (Figure 1).
    Elicitation and Production of Triterenoids (Célastrol and derivatives):
    A volume of about 1000 ml of bag A culture (5 L) is transferred to bag B placed next to bag A on the same tray. The medium of the bag A is supplemented with 1000 ml of concentrated medium in demineralized water having the following composition: Macroelements: NH4NC> 3 at 13.9 g / L, KN03 at 15.2 g / L, CaCl2.2H2O at 2.2 g / L, 370 mg / L MgSO 4 .7H 2 O, 170 mg / L KH 2 PO 4; Microelements: KI at 0.83 mg / L, H3BO3 at 31.2 mg / L, MnSO4.4H2O at 91.5 mg / L, ZnSO4 .H2O at 33.05 mg / L, Na2MoO4.2H2O at 1.25 mg / L, CuS04.5H2O at 0.125 mg / L, CoCl2.6H2O at 0.125 mg / L, FeS04.7H2O at 139 mg / L, Na2EDTA.2H2O at 186.5 mg / L; Vitamins: myo-inositol at 1250 mg / L, nicotinic acid at 8.5 mg / L, pyridoxine-HCl at 5 mg / L, thiamine-HCl at 5 mg / L; Amino acid: glycine at 20 mg / L; Source of carbon: sucrose at 150 g / L; to which the following elicitation cocktail is added: sodium pyruvate 7.5 g / L, potassium pyrophosphate 2.2 g / L, 2 iP 0.002 g / L, methyl jasmonate 1.8 g / L and chitin 10 g / L.
    The contents of the bag A is thus elicited with stirring at a temperature of 27 ° C.
    Culture in the elicitation phase is followed by measurement of cell growth and Celastrol concentration in the culture for 16 days (Figure 1).
    It can be seen that the concentration of Celastrol in the pocket A increases regularly until day 32 and is at its maximum at 553 mg per liter of elicitation medium after 15 days of incubation.
    The rate of production of Celastrol is approximately 46 mg / L of cell suspension and per day during the 15 days after elicitation until J32.
    The production kinetics of Celastrol begin to decline shortly after consuming almost all of the available sucrose (Figure 1).
    EXAMPLE 5 Production of a Celastrol-enriched Extract by Solid / Liquid Extraction of the Biomass Resulting from Tripterygium wilfordii Cell Suspension (TW08) At 15 days after elicitation (32 days after inoculation), the majority of the biomass is recovered by filtration of the cell suspension with a nylon filter (20 - 50μΜ) (TW08). From 5 L of suspension, approximately 1925 g of biomass are recovered. This biomass is extracted with ethyl acetate (still isopropyl acetate) in a proportion of 2: 1 (Vol: Weight) relative to the weight of biomass (here 3850 ml of solvent for 1925 g of biomass ). The biomass / solvent mixture is then physically extracted by sonication. The organic phase is then recovered after maceration with stirring. The addition of solvent (followed by maceration with stirring and recovery of the organic phase) is repeated twice.
    The concentration of Celastrol and derivatives in the organic phase is measured by HPLC assay (Celastrol quantification, Tingenin derivatives) (see Figure 2). Experimental conditions: Waters Atlantis dC18 column 4.6x150 mm - 5μ equipped with an Atlantis dC18 guard column 5 μm 4.6 x 20 mm Gd Column - 5μ. Mobile phases: (A) 0.1 mM ammonium acetate pH 4.0 (B) 0.1 mM ammonium acetate pH 4.0 in 99.8% acetonitrile. Gradient: initial 25% (A) / 75% (B) - 20min 0% (A)% 100% (B) - 24.5min 0% (A) / 100% (B) - 25min 25% (A) / 75% (B) - 30min 25% (A) / 75% (B). Flow rate: 1 mL / min. Detection at 426nm: retention peaks (min): Tingenin B (6.5), Tingenin A (8.2), Celastrol (10.5).
    Example 6 Purification of Celastrol from Tripterygium wilfordii Culture From the extract obtained in Example 5, ethyl acetate (or isopropyl acetate) is evaporated under reduced pressure in order to obtain a dry extract. Part of the extract thus obtained is purified initially by medium pressure liquid chromatography (CLMP) on silica (40 g, 125x25 mm, 30 μm) with a CH 2 Cl 2 / MeOH elution gradient (100/0 to 0 / 100). All the fractions obtained are analyzed by thin layer chromatography (TLC - stationary phase: Silica 60 A, mobile phase: toluene / ethyl acetate / acetic acid 70: 33: 3) and the fractions containing predominantly Celastrol and its derivatives Tingenin (A and B) are collected. In a second step, the fraction containing the products of interest (Célastrol and derivatives) is purified by reverse phase high performance liquid chromatography (HPLC) (Lichrospher 100RP18, 250x25mm, 5μΜ) with a linear gradient Water / Acetonitrile / 0.1 % formic acid (80/20 to 0/100). The Celastrol peak is collected and concentrated under reduced pressure, approximately 2.5 to 3 g of Celastrol are obtained from 5 L of starting culture suspension. Optionally, it can be crystallized to have absolute purity.
    In parallel, part of the dry extract obtained is taken up in a buffer to give the extract R003034 which will be evaluated in anti-Th17 pharmacological activity.
    Example 7: Anti-Th17 Activity on Human CD4 + Cells of the CCV Extract Enriched with Celastrol
    In inflammatory dermatoses (especially in psoriasis), it is known that CD4 + T cells overexpress interleukins IL17, IL6 and IL22, as well as IFN gamma and TNF alpha. In the case of atopic dermatitis, IL17 is overexpressed in a certain phase of the pathology. In addition, the Th17 pathway is strongly activated in case of acne. The inhibitory power of an enriched extract according to the invention on the overexpression of these molecules has been tested.
    Human CD4 + cells were isolated from the blood mononuclear cells of 2 donors on Ficoll Paque plus® according to the protocol recommended by the manufacturer (GE Flealthcare). The CD4 + lymphocytes are isolated by positive sorting with the Miltenyi Biotec kit (CD4) and an LS column column and resuspended in RPMI culture medium (Sigma-Aldrich: containing L-glutamine and 10% fetal bovine serum). ) supplemented with 100 μg / ml streptomycin and 100 U / ml penicillin. The suspended lymphocytes are distributed in microplate wells. Different extracts or controls are then added to the wells: 1. negative control (the same volume of buffer without reagent is added); 2. R003034 extract at 0.06 mg / ml (Celastrol titrated at 9 ng / ml) (final concentration in the well); 3. 0.2 mg / ml extract R003034 (Celastrol titrated to 30 ng / ml) (final concentration in the well); 4. R003034 extract at 0.6 mg / ml (Celastrol titrated at 90 ng / ml) (final concentration in the well); Dexamethasone at 2 μΜ (positive control) (final concentration in the well).
    After 2 hours of incubation at room temperature, the CD4 + lymphocytes are activated at 37 ° C. for 20 hours with anti-CD3 and anti-CD28 antibodies at a final concentration of 300 ng / ml and 400 ng / ml, respectively. Anti-CD3 and anti-CD28 antibodies are known to induce a Th17 type response.
    The cytokines IL-17A, INF gamma, IL-22, TNF alpha and IL-6 were quantified in the supernatant of each tube by the method of Multiplex Immunoassays (Jager et al., 2003). The results obtained are from 2 experiments with lymphocytes from 2 different donors. The results are shown in Figures 3 to 7 as a percentage of induction relative to the negative control (1). It is found that: the positive control 5 (dexamethasone (2 μl)) inhibits the overexpression of all cytokines: IL-17A, INF gamma, IL-22, TNF alpha and IL-6; the extract according to the invention (2, 3 and 4) strongly inhibits the overexpression of cytokines IL-17A, INF gamma, IL-22, TNF alpha and IL-6. The inhibition of IL-17A and TNF alpha overexpression is dose-dependent. At the lowest dose, titrated at 9 ng / ml in Celastrol, 75% inhibition of NL-17A overexpression, 80% inhibition of TNF alpha overexpression and almost complete inhibition of overexpression of INF-gamma, IL-22 and IL-6.
    This demonstrates that the extract R003034 has a very strong anti-Th17 activity, comparable if not greater than dexamethasone (2 μΜ), which gives it a remarkable activity in the treatment of Th17-dependent pathologies such as psoriasis, acne and atopic dermatitis. REFERENCES :
    Camelio stallion JACS 2015, 137: 11864-67 Stalled coppede. Plant Cell Tiss. Cooked Organ. 2014, 118: 33-43 Jageretal. Clin. Diagn. Lab. Immunol. 2003, 10 (1): 133-9 Kelhala stall. PLOS One 2014, 9 (8): e105238 Liu stall. J. Asian Nat. Prod. Res. 2016, 19: 1-10 Lowes et al. Annu. Rev. Immunol. 2014, 32: 227 Miyagaki stallion. J. Derm. Science 2015, 78:89 Murashige &amp; Skoog Physiol. Plant. 1962, 15: 473-497
    权利要求:
    Claims (14)
    [1" id="c-fr-0001]
    A process for producing a crude extract enriched in pentacyclic triterpenes comprising the following steps: (i) a cell proliferation phase of a plant of the family Celastraceae in a proliferation medium, (ii) a phase of elicitation by adding an elicitation cocktail to the cell culture obtained in step (i), said elicitation cocktail comprising at least one elicitor of the monocarboxylic compound type and at least one biotic elicitor, and (iii) the preparation of a crude extract enriched with pentacyclic tripterpenes from the cell culture obtained in step (ii).
    [2" id="c-fr-0002]
    2. Process for producing an enriched crude extract according to claim 1, wherein the biotic elicitor is an N-acetylaminoglucosamine, especially chitin.
    [3" id="c-fr-0003]
    A process for producing a crude enriched extract according to claim 1 or 2, wherein the monocarboxylic compound elicitor is a methyl ester, especially methyl jasmonate.
    [4" id="c-fr-0004]
    The process for producing an enriched crude extract according to any one of claims 1 to 3, wherein the elicitation cocktail further comprises at least one plant cell differentiation factor and at least one precursor of the pathway. synthesis of terpenes.
    [5" id="c-fr-0005]
    A process for producing an enriched crude extract according to claim 4, wherein the at least one cell differentiating factor of the plant cells is selected from a cytokine, a gibberillin and a mixture thereof, especially from benzylaminopurine ( BAP), 6-γ, γ-dimethylallylaminopurine (2iP) and a mixture thereof.
    [6" id="c-fr-0006]
    A process for producing an enriched crude extract according to claim 4 or 5, wherein the at least one terpenes synthesis precursor is selected from the group consisting of sodium pyruvate, potassium pyrophosphate and a mixture of those -this.
    [7" id="c-fr-0007]
    A process for producing an enriched crude extract according to any one of claims 1 to 6, wherein the pentacyclic triterpene is selected from the group consisting of Celastrol, Tingenin A, Tingenin B, Pristimerin, Tripterygone. and their mixtures.
    [8" id="c-fr-0008]
    The process for producing an enriched crude extract according to claim 7, wherein the pentacyclic triterpene is Celastrol.
    [9" id="c-fr-0009]
    A process for producing an enriched crude extract according to any one of claims 1 to 8, further comprising a step (iv) of obtaining a purified extract of one or more pentacyclic triterpenes from the enriched crude extract obtained in step (iii).
    [10" id="c-fr-0010]
    An enriched crude extract obtainable by the process according to any one of claims 1 to 8.
    [11" id="c-fr-0011]
    The enriched crude extract of claim 10 for use as a medicament.
    [12" id="c-fr-0012]
    12. The crude extract enriched for its use according to claim 11, in the treatment of an inflammatory dermatitis inducing a TH 17 type immune response.
    [13" id="c-fr-0013]
    The enriched crude extract for its use according to claim 12, wherein the inflammatory dermatosis is selected from the group consisting of psoriasis, atopic dermatitis and acne.
    [14" id="c-fr-0014]
    14. A pharmaceutical or dermocosmetic composition comprising an enriched crude extract according to claim 10.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP4769868B2|2011-09-07|Method for producing corosolic acid by plant cell suspension culture
    FR3051116B1|2019-06-07|PROCESS FOR PRODUCING CELASTROL AND PENTACYCLIC TRITERPENIC DERIVATIVES
    EP2710113B1|2016-12-28|Novel strain of microalga that produces squalene
    CN106688889B|2018-08-31|The method for improving cucurbit diene alcohol content in Siraitia grosvenorii
    EP2710131B1|2019-02-27|Method of preparation and extraction of squalene from microalgae
    EP2496708B1|2017-03-01|Method for producing triptolide
    US20050255569A1|2005-11-17|Method for producing triterpene composition
    RU2639566C1|2017-12-21|CALUS STRAIN OF CULTURED TURKESTANIAN AJUGA TURKESTANICA | Briq. PLANT CELLS IN VITRO - TURKESTERONE PRODUCER
    EP3471837B1|2020-08-12|Extract of undifferentiated cells of mimosa pudica and uses thereof in dermo-cosmetics
    RU2296155C1|2007-03-27|Strain of cultured cells of plants serratula coronata l
    JP2008000081A|2008-01-10|New cinnamic acid derivative, method for producing the same and fermented product of propolis
    Lee et al.2001|Effect of culture conditions on the biosynthesis of gagaminine, a potent antioxidant from the roots of Cynanchum wilfordii
    FR3073398A1|2019-05-17|PENTACYCLIC TRITERPENES IN THE TREATMENT OF A BUCCO-DENTAL PATHOLOGY
    RU2757463C1|2021-10-18|Method for increasing efficiency of cultivating callus culture of chinese magnolia vine | baill.), in vitro conditions
    FR3095754A1|2020-11-13|Pentacyclic triterpenes in the treatment of vitiligo
    JP2001261691A|2001-09-26|Compound containing antioxidative activity, composition useful as food integrator containing the compound and method for producing the compound
    JP5927199B2|2016-06-01|Method for producing lauric acid-containing fat and oil and lauric acid or ester thereof
    FR3075641A1|2019-06-28|COSMETIC USE OF A CELLULAR CULTURE MEDIUM AS AN ACTIVE AGENT FOR THE CARE OF KERATINIC MATTER
    Matas0|Plant cell suspension cultures: establishment, optimization, characterization and biotechnological applications
    Srivastava et al.2009|Aspergillus sydowii
    Srivastava et al.2009|Production of Azadirachtin in Anther Cultures of Azadirachta indica A. Juss., and Its Bioactivity Against Aspergillus sydowii.
    Madhavan et al.2010|Biochemical changes in the four morphogenic pathways of invitro cultures in Datura metel Linn
    CH438577A|1967-06-30|Process for the production of mitotic substances
    同族专利:
    公开号 | 公开日
    SG11201809948XA|2018-12-28|
    CA3023192A1|2017-11-16|
    MX2018013728A|2019-08-01|
    US20190134128A1|2019-05-09|
    PT3454875T|2020-12-11|
    ES2831835T3|2021-06-09|
    EP3454875B1|2020-09-23|
    WO2017194757A1|2017-11-16|
    RU2743715C1|2021-02-24|
    EP3454875A1|2019-03-20|
    BR112018073117A2|2019-03-06|
    FR3051116B1|2019-06-07|
    KR20190006523A|2019-01-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FR2952072A1|2009-11-05|2011-05-06|Pf Medicament|PROCESS FOR PRODUCING TRIPTOLIDE|
    FR3047665B1|2016-02-17|2020-12-11|Pf Medicament|CELASTROL AND ITS DERIVATIVES IN THE TREATMENT OF PRE-CANCEROUS SKIN TUMORS AND PATHOLOGIES|
    LU101117B1|2019-02-07|2020-08-07|Luxembourg Institute Of Science And Tech |METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS|
    FR3095754B1|2019-05-10|2021-11-19|Fabre Pierre Dermo Cosmetique|Pentacyclic triterpenes in the treatment of vitiligo|
    法律状态:
    2017-05-30| PLFP| Fee payment|Year of fee payment: 2 |
    2017-11-17| PLSC| Search report ready|Effective date: 20171117 |
    2018-05-28| PLFP| Fee payment|Year of fee payment: 3 |
    2019-05-31| PLFP| Fee payment|Year of fee payment: 4 |
    2020-05-30| PLFP| Fee payment|Year of fee payment: 5 |
    2021-05-31| PLFP| Fee payment|Year of fee payment: 6 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1654240A|FR3051116B1|2016-05-12|2016-05-12|PROCESS FOR PRODUCING CELASTROL AND PENTACYCLIC TRITERPENIC DERIVATIVES|
    FR1654240|2016-05-12|FR1654240A| FR3051116B1|2016-05-12|2016-05-12|PROCESS FOR PRODUCING CELASTROL AND PENTACYCLIC TRITERPENIC DERIVATIVES|
    RU2018141358A| RU2743715C1|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives|
    CA3023192A| CA3023192A1|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives|
    PT177220712T| PT3454875T|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives|
    SG11201809948XA| SG11201809948XA|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives|
    US16/099,952| US20190134128A1|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives|
    BR112018073117-0A| BR112018073117A2|2016-05-12|2017-05-12|method for the production of celastrol and pentacyclic triterpene derivatives|
    PCT/EP2017/061504| WO2017194757A1|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives|
    ES17722071T| ES2831835T3|2016-05-12|2017-05-12|Production method of Celastrol and pentacyclic triterpenic derivatives|
    EP17722071.2A| EP3454875B1|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives|
    MX2018013728A| MX2018013728A|2016-05-12|2017-05-12|Method for producing celastrol and pentacyclic triterpene derivatives.|
    KR1020187035725A| KR20190006523A|2016-05-12|2017-05-12|A method for preparing selastrol and pentacyclic triterpene derivatives|
    [返回顶部]